Pirfenidone
Platelet Storage Pool Deficiency
William Gahl, M.D.Small moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Platelet Storage Pool Deficiency cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
N-Acetyl-L-Cysteine National Human Genome Research Institute (NHGRI) | Phase 2 | BB |
Zileuton National Human Genome Research Institute (NHGRI) | Phase 1/2 | CCC |
Losartan National Human Genome Research Institute (NHGRI) | Phase 1/2 | CCC |
Erythromycin National Human Genome Research Institute (NHGRI) | Phase 1/2 | CCC |
PRAVASTATIN National Human Genome Research Institute (NHGRI) | Phase 1/2 | CCC |
Same molecule, other indications
Pirfenidone is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →